Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Extensions also allow time for the MMs to cover!!
also, they are saying....Please judge don't penalize us for the time, you are hurting family members (and kids) by not allowing them to go on vacation with their parents...
They are stooping really low!!
Family vacations usually happens when school is out.
They are squirming.
"
I didn't see that....Did she ask for an injunction in the 2nd amendment just filed?
And it keeps on getting hit and no change in ask price....some kind of message today with all those 2,500 blocks on the offer.
How F'd up is this....
CDEL has an offer of 2,500 shares at .5099.....0ver 83,000 shares went off at .5099 and the ask didn't move.
They are covering and not hiding it!
It's hard for me to fathom with 1.7m pages the MHRA would not have at least one question.
And I am guessing the questions will be handed over to NWBO on Thursday or Friday.
I just hope the questions could be easily answered and not run the full 60 days.
Today is day 90 from submission.
Three year member and first post???
Hmmm!
Lots of price swings to entice selling so the shorts can cover.
We will see a positive close, if the covering continues.
Thank you for the clarification....Still interesting that it changed from "Jury Trial" to "Plaintiff"
Looks like the change went from Jury trial to Plaintiff? Perhaps a deal?
LOL!!!
Head of schedule means squat....Results are guaranteed to be late...will take years to find a result that can be spinned....
Also, it looks like 2-73 is dead and now on the 3-7...Can't believe Chris is still around...
Happy I got out before Christmas...Now to get removed from the worthless PRs...
March 21/22 is most likely when the RFI will be given to NWBO...If no RFI then we await another 60 days perhaps...until then we will slowly dropped unless we get some type of good news.
Funny how his narrative's change with the mention of a pending lawsuit.
Earlier he was dishing the trials claiming fake data and the MHRA and NICE would never approve such a scam.
Now he states the obvious that MHRA and NICE will be doing their job and perform proper due diligence....DUH
His beef is with King's College (and the nurse) and they are not taking his claims lightly, I suppose
Most Likely .52...Until we hear news of approval, the share price will not be going anywhere.
News of approval will set everything else...
Perhaps if you ship them a case of Geritol they might get enough energy to appease you.
Have you noticed all of your complaining has resulted in squat?
No other choice right now then to go with the flow...It will happen soon enough.
Do the defendants get an opportunity to challenge the loss causations or is this final before ultimate decision to dismiss MTD?
If loss causation is cut and dry, then I would like to see a filing around 3:00 in order to see what the market does in response to a clear cut loss causation.
I do not see any mention of DCVax.
Vote 12 - 2 in favor Benefit outweigh risk.
Listening to this, I believe the FDA will approve.
FDA ODAC Live meeting...
When NICE ascertains price, is a drug/treatment allowed to be priced higher and NICE only pays what they state?
Meaning if NICE says DCVax is only reimbursed for 150k, can the ultimate charge be 200k and the difference is considered out of pocket or what NICe states is the max it can be charged?
Most likely we close down with a trade after 4:00:00...The MMs never show an uptick post 4:00 as the close, however they do not hesitate to show the downtick as a close.
How about that we close green!!
I can recall ever seeing so many 100 share trades as today. Most likely the bots trading among themselves with some short covering in between.
No buyers (except for the short) and no sellers.
Just need news to drive volume.
Looks like they are happy making a penny spread on the 100 share trades
UPDATE 2-US FDA staff raises concerns on Geron's blood disorder drug
8
002722.SZ
+1.24%
Christy Santhosh and Pratik Jain
Updated Tue, March 12, 2024 at 9:55 AM CDT
In this article:
002722.SZ
+1.24%
(Adds statement from staff reviewers paragraph 5 onwards, analyst comment in paragraph 9)
By Christy Santhosh and Pratik Jain
March 12 (Reuters) - The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment.
Geron is seeking approval of the injectable drug, called imetelstat, for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS).
The drug, if approved, will compete with Bristol Myers Squibb's Reblozyl, which has been approved by the FDA for the same disease indication.
Last year in January, Geron CEO John Scarlett told Reuters that the company anticipates a peak market potential of $1.2 billion for imetelstat in the United States and some key EU countries by 2030.
While Geron's drug met the main goal of increasing independence from transfusion at eight weeks in a late-stage study, the FDA's staff said the "clinical meaningfulness" of the data was unclear.
"The general consensus among MDS experts has been that only a 16-week or longer period of transfusion independence is clinically meaningful," the agency's staff said ahead of a meeting of FDA's independent advisers scheduled for Thursday.
The agency said that while the drug is believed to work by treating the underlying cancer, the study did not show a "disease-modifying effect" in either extending survival or helping drive disease remission.
It also highlighted a high rate of low red blood cell count in the late-stage study.
Wedbush analyst Robert Driscoll said it was expected that the briefing documents would lean negative and added that Geron will be able to provide a strong case against the points made by the FDA. (Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Lets see what the advisory committee recommends on Thursday.
Yes, adverse effects were more in treat arm than placebo....means it's working...benefits outweigh risk?
We will learn on Thursday.
Almost two cents spread...What happen to the .0001 spreads?